Abstract
Trypsin, chymotrypsin and elastase were combined to hydrolyze scorpion Buthus marstesii Karsch powders to prepare scorpion peptides (SP). Orthogonal design experiment L16 (44) was used to optimize variables of enzymolysis temperature, time, pH and enzyme concentration. Degree of hydrolysis (DH) and inhibition rate (IR) of A549 cells were selected as analysis indicators. The optimum enzymolysis conditions were determined as follows: enzymolysis temperature 40°C, time 3h, pH 8.5 and enzyme concentration of each 2000U. The anti-tumor activity of SP was determined on a panel of representative cell lines (A549, MCF7 and EC109) using MTT assay. In vitro, SP significantly inhibited the proliferation of A549, which was more obvious than MCF-7 and EC109. Further experiments on cell apoptosis and cell cycle analysis revealed that SP induce apoptosis and arrest cell cycle progression in S phase.
Keywords: Orthogonal design experiment, enzymolysis conditions, anti-tumor activity, cell apoptosis, cell cycle analysis.
Graphical Abstract
Current Signal Transduction Therapy
Title:Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Volume: 11 Issue: 1
Author(s): Fangwen Jiao, Jihui Wang, Yuhong Liu, Yan Zou, Wei Jia, Panpan Zhang, Jing Sun, Youwei Xu and Junxiang Wang
Affiliation:
Keywords: Orthogonal design experiment, enzymolysis conditions, anti-tumor activity, cell apoptosis, cell cycle analysis.
Abstract: Trypsin, chymotrypsin and elastase were combined to hydrolyze scorpion Buthus marstesii Karsch powders to prepare scorpion peptides (SP). Orthogonal design experiment L16 (44) was used to optimize variables of enzymolysis temperature, time, pH and enzyme concentration. Degree of hydrolysis (DH) and inhibition rate (IR) of A549 cells were selected as analysis indicators. The optimum enzymolysis conditions were determined as follows: enzymolysis temperature 40°C, time 3h, pH 8.5 and enzyme concentration of each 2000U. The anti-tumor activity of SP was determined on a panel of representative cell lines (A549, MCF7 and EC109) using MTT assay. In vitro, SP significantly inhibited the proliferation of A549, which was more obvious than MCF-7 and EC109. Further experiments on cell apoptosis and cell cycle analysis revealed that SP induce apoptosis and arrest cell cycle progression in S phase.
Export Options
About this article
Cite this article as:
Jiao Fangwen, Wang Jihui, Liu Yuhong, Zou Yan, Jia Wei, Zhang Panpan, Sun Jing, Xu Youwei and Wang Junxiang, Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity, Current Signal Transduction Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574362411666160517113916
DOI https://dx.doi.org/10.2174/1574362411666160517113916 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Current Molecular Medicine Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer
Current Cancer Drug Targets New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets